Is Ado-trastuzumab emtansine TDM1?

Ado-trastuzumab emtansine, sold under the trade nameKadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody Herceptin covalently linked to the cytotoxic agent DM1.

Trastuzumab alone halts the growth of cancer cells by binding to the HER2 receptor, while Trastuzumab undergoes receptor-mediated cellular internalization and is catabolized in lysosomes, where it releases DM1-containing catabolites and subsequently binds to tubulin, leading to mitotic arrest and cell death. The binding of trastuzumab to HER2 prevents homodimerization or heterodimerization of the receptor (HER2/HER3), ultimately inhibiting the activation of MAPK and PI3K/AKT cell signaling pathways. Because the monoclonal antibody targets HER2, and HER2 is only overexpressed in cancer cells, the conjugate specifically delivers the cytotoxic agent DM1 to tumor cells. The conjugate is abbreviated as T-DM1. SotrastuzumabisT-DM1.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.